HLA-A and myxoid/round cell liposarcoma: A phase I/II pilot study administered autologous specific peptide enhanced affinity receptor (SPEAR) T cells recognizing an NY-ESO-1 peptide complexed with HLA-A*02 to patients with MRCLS and specific HLA-A*02 haplotypes.